Welford, R., Mühleman, A., Priestman, D., Garzotti, M., Deymier, C., Ertel, E., . . . Probst, M. (2017). Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence. Karger.
Chicago Style (17th ed.) CitationWelford, R., et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence. Karger, 2017.
MLA (9th ed.) CitationWelford, R., et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence. Karger, 2017.
Warning: These citations may not always be 100% accurate.